Pitfalls and premature failure of the Freedom SOLO stentless valve

Abstract

The FS stentless valve is safe to implant and shows satisfying mid-term results in our single institution experience. Freedom from SVD and explantation decreased markedly after only 6-7 years, so that patients with FS require close observation and follow-up. Exact sizing, symmetric positioning and observing patient limitations are crucial for optimal outcome.

Pericardial Stentless Valve for Aortic Valve Replacement: Long-Term Results

“…In two recent reports from Berne, Switzerland [27], the incidence of explants for SVD was considerably high, but in most of them, a clear association between incorrect implantation and need for reoperation could be identified. Oversizing and undersizing are probably the most frequent errors: leaflets are wrinkled at the level of the suture line, with reduced mobility, higher gradients, and irregular coaptation leading to structural failure.…”

Solo Smart Stentless Bioprosthesis for Infective Valve Endocarditis with Aortic Annular Abscess

“…Therefore, better outcomes with the SS stentless valve depend on optimal patient selection and on recognizing its limitations. 8,11) In conclusion, high-risk patients with infective endocarditis accompanied by annular abscess, a small aortic annulus, and those who require concomitant mitral valve surgery and redo AVR may profit from SS stentless valve implantation.…”

Solo Smart stentless bioprosthesis for redo aortic valve replacement

“…The stentless valve may be more resistant to SVD; however, because it is early in the follow‐up period, this fact cannot be confirmed. It was reported that freedom from the SVD of the Solo valve decreased markedly after only 6 to 7 years; therefore, further, careful observation is required.…”